Finanzen von Phio Pharmaceuticals Corp (PHIO)PHIOPhio Pharmaceuticals Corp

Evaluating the bottom line, Phio Pharmaceuticals Corp maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -113.71%, provide a clear picture of how effectively PHIO converts its operational activities into shareholder value.

In the context of the broader market, PHIO competes directly with industry leaders such as CALC and RGNT. With a market capitalization of $9.56M, it holds a leading position in the sector. When comparing efficiency, PHIO's gross margin of N/A stands against CALC's N/A and RGNT's N/A. Such benchmarking helps identify whether Phio Pharmaceuticals Corp is trading at a premium or discount relative to its financial performance.

Phio Pharmaceuticals has reported continuous losses, with net income losses of -$4,003,000 in Q1 2026 and a gross profit of $0.00 in Q4 2024, indicating severe operational challenges.